FDA
-
-
-
-
-
-
-
Aligos Therapeutics Enters into Exclusive License Deal with Xiamen Amoytop Biotech Co., Ltd. to Develop and Commercialize Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection
-
-
-
-
-
-
-
Aligos begins phase 2 trial for hepatitis B treatment ALG-000184
-
-
-
-
-
-
-
Piper Sandler Reiterates Overweight Rating on Aligos Therapeutics Inc. (ALGS)
-
-
-
-
-
-
-
Aligos Therapeutics Inc. (ALGS) Presents 28-Day Safety, Efficacy and Pharmacokinetic Clinical Data for ALG-000184
-
-
-
330,681 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

